The Phase III pipeline for ovarian cancer

Doubling down on validated mechanisms through combinations and next-in-class agents defines much of the Phase III pipeline for ovarian cancer, with a handful of companies venturing into new biology and therapeutic modalities.

The 15 therapies in Phase III trials for ovarian cancer work by four major mechanisms, two of which are already approved for the disease: angiogenesis and DNA damage repair inhibition. VEGF receptors remain the target of choice for anti-angiogenic agents, alone or in combination, but at least one company has different approach to disrupting the tumor vasculature. ...